Bill Detail
H.R. 6485
Congress: 119
Title
Skinny Labels, Big Savings Act
Summary
Skinny Labels, Big Savings Act This bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs. Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics. The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act: submitting or seeking approval of a skinny label for a generic or biosimilar drug; promoting or commercially marketing a drug with skinny labeling approved by the FDA; or describing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug. The bill also applies the safe harbor to similar actions under the Public Health Service Act.
Sponsor
Rep. Ben Cline [R-VA-6]
Status
Referred to the House Committee on the Judiciary.
Status as of Nov 13, 2026, 3:10 PM · synced 3d ago
Introduced
2025-12-05
Data source mode: congress-gov
Bill Engagement
Skinny Labels, Big Savings Act This bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval fo…
Lobbyists on the case
These are cached disclosure mentions, not verified current representation or confirmed event attendance.
- Pharmaceutical Research and Manufacturers of America2 filings · 13 lobs
- Bart Forsyth2026 Q1
- Elisabeth Fox2026 Q1
Limited preview · paid intelligence
Keep the intelligence current—not just this one record.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.
Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.
SEE A FINISHED HEALTHCARE EXAMPLE
Three days of Hill visits. Two Medicare access questions.
A separate, source-linked editorial example—not a dossier about this bill, an endorsement, or a claim of participation. The full records stay paid.
Read the finished healthcare brief →After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.